Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210

被引：35
|
作者：
Balar, Arjun Vasant
Dreicer, Robert
Loriot, Yohann
Perez-Gracia, Jose Luis
Hoffman-Censits, Jean H.
Petrylak, Daniel Peter
Van Der Heijden, Michiel Simon
Ding, Beiying
Shen, Xiaodong
Rosenberg, Jonathan E.
机构：
[1] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[2] Univ Virginia, Emily Couric Clin Canc Ctr, Charlottesville, VA USA
[3] Gustave Roussy, Villejuif, France
[4] Clin Univ Navarra, Pamplona, Spain
[5] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
[6] Yale Univ, Sch Med, New Haven, CT USA
[7] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[8] Netherlands Canc Inst, Dept Med Oncol, San Francisco, CA USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4523
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
    Vuky, Jacqueline
    Balar, Arjun Vasant
    Castellano, Daniel E.
    O'Donnell, Peter H.
    Grivas, Petros
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Hahn, Noah M.
    De Wit, Ronald
    Savage, Mary
    Pang, Lei
    Frenkl, Tara L.
    Keefe, Stephen Michael
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
    Rosenberg, Jonathan E.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    Penel, Nicolas
    Zagonel, Vittorina
    Sierecki, Mitchell Robert
    Bao, Weichao
    Zhou, Yinghui
    Ellinghaus, Peter
    Sweis, Randy F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.
    Galsky, Matt D.
    Arija, Jose Angel Arranz
    De Santis, Maria
    Davis, Ian D.
    Bamias, Aristotelis
    Kikuchi, Eiji
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    O'Donnell, Peter H.
    Bernhard, Sandrine
    Lee, Chooi Peng
    Bene-Tchaleu, Fabiola
    Mariathasan, Sanjeev
    Grande, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [34] KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)-Updated response and survival results.
    O'Donnell, Peter H.
    Balar, Arjun Vasant
    Vuky, Jacqueline
    Castellano, Daniel E.
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Grivas, Petros
    Hahn, Noah M.
    Plimack, Elizabeth R.
    Savage, Mary J.
    Fang, Xiao
    Godwin, James Luke
    Frenkl, Tara L.
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
    Gupta, Shilpa
    Rosenberg, Jonathan E.
    Mckay, Rana R.
    Flaig, Thomas W.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Friedlander, Terence W.
    Bilen, Mehmet Asim
    Srinivas, Sandy
    Burgess, Earle F.
    Merchan, Jaime R.
    Tagawa, Scott T.
    Brown, Jason R.
    Yu, Yao
    Carret, Anne-Sophie
    Wirtz, Heidi
    Guseva, Maria
    Moreno, Blanca Homet
    Milowsky, Matthew I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
    Bamias, Aristotelis
    Davis, Ian D.
    Galsky, Matt D.
    Arija, Jose Angel Arranz
    Kikuchi, Eiji
    Grande, Enrique
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    Bene-Tchaleu, Fabiola
    Mariathasan, Sanjeev
    Lee, Chooi Peng
    Bernhard, Sandrine
    De Santis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [37] BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)
    Rosenberg, J. E.
    Bajorin, D. F.
    Smith, A.
    D'Cruz, C.
    Lanasa, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
    O'Donnell, Peter H.
    Balar, Arjun Vasant
    Vuky, Jacqueline
    Castellano, Daniel
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Grivas, Petros
    Hahn, Noah M.
    Plimack, Elizabeth R.
    Xu, Jin Zhi
    Godwin, James Luke
    Moreno, Blanca Homet
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) plus platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.
    Galsky, Matt D.
    Banchereau, Romain
    Hamidi, Habib Rahman
    Leng, Ning
    Harris, Will
    Peter, H. O.
    Kadel, Edward Ernest
    Yuen, Kobe Chi Yung
    Jin, Dexter
    Koeppen, Hartmut
    Tayama, Darren
    Grande, Enrique
    Arranz, Jose
    De Santis, Maria
    Davis, Ian D.
    Kikuchi, Eiji
    Shen, Xiaodong
    Bamias, Aristotelis
    Mariathasan, Sanjeev
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130.
    Galsky, Matthew D.
    Arranz, Jose Angel
    Grande, Enrique
    De Santis, Maria
    Davis, Ian D.
    Kikuchi, Eiji
    Garcia del Muro, Xavier
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    O'Donnell, Peter H.
    Shen, Xiaodong
    Lee, Chooi
    Mecke, Almut
    Mariathasan, Sanjeev
    Bamias, Aristotelis
    CANCER RESEARCH, 2021, 81 (13)
12345